HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% Drug Patent Profile
✉ Email this page to a colleague
When do Heparin Sodium 25,000 Units In Dextrose 5% patents expire, and when can generic versions of Heparin Sodium 25,000 Units In Dextrose 5% launch?
Heparin Sodium 25,000 Units In Dextrose 5% is a drug marketed by Fresenius Kabi Usa, Hospira, and B Braun. and is included in six NDAs.
The generic ingredient in HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% is heparin sodium. There are seventy-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Heparin Sodium 25,000 Units In Dextrose 5%
A generic version of HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% was approved as heparin sodium by HOSPIRA on April 28th, 1983.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%?
- What are the global sales for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%?
- What is Average Wholesale Price for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%?
Summary for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 8 |
| Clinical Trials: | 98 |
| DailyMed Link: | HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% at DailyMed |
Recent Clinical Trials for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vaneltix Pharma, Inc. | Phase 2 |
| Prevail Infoworks, Inc | Phase 2 |
| The First Affiliated Hospital with Nanjing Medical University | N/A |
See all HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% clinical trials
Pharmacology for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
| Drug Class | Anti-coagulant Unfractionated Heparin |
US Patents and Regulatory Information for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% | heparin sodium | INJECTABLE;INJECTION | 017029-022 | Aug 24, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| B Braun | HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | heparin sodium | INJECTABLE;INJECTION | 019952-005 | Jul 20, 1992 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% | heparin sodium | INJECTABLE;INJECTION | 018911-008 | Jan 30, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | heparin sodium | INJECTABLE;INJECTION | 019339-004 | Mar 27, 1985 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fresenius Kabi Usa | HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% | heparin sodium | INJECTABLE;INJECTION | 017029-023 | Aug 24, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
